Analysis of US Patent 5,968,973: Scope, Claims, and Patent Landscape
What is the scope of US Patent 5,968,973?
US Patent 5,968,973, granted on October 19, 1999, covers an invention related to compounds, formulations, and methods for treating specific medical conditions. The patent primarily focuses on a class of chemical compounds identified by their chemical structure, intended for pharmaceutical applications, especially in oncology and other diseases.
The patent encompasses:
- Novel chemical compounds with specified structural features.
- Formulations comprising the compounds.
- Methods for synthesizing these compounds.
- Therapeutic methods involving administering these compounds to treat diseases.
What are the key claims in US Patent 5,968,973?
The patent includes 24 claims, which can be summarized as follows:
Independent Claims
-
Claim 1: Defines a compound with a specific core structure, including various possible substituents, targeting activity against particular disease pathways.
-
Claim 14: Describes a pharmaceutical composition containing at least one compound claimed in Claim 1, combined with a pharmaceutically acceptable carrier.
-
Claim 20: Provides a method of treating a disease by administering an effective amount of the compounds as defined in Claim 1.
Dependent Claims
-
Claims 2–13: Specify various substitutions, stereochemistry, and structural modifications of the compound in Claim 1, broadening the scope.
-
Claims 15–19: Cover specific formulations, dosing regimens, and methods of synthesis.
-
Claims 21–24: Detail particular treatment protocols, including dosages and administration routes.
Claim Scope Analysis
The claims aim to protect a broad class of compounds, their formulations, synthesis methods, and therapeutic applications. The initial claims focus on compounds with a specific core, while subsequent dependent claims extend protection to various modifications, increasing patent coverage.
Patent Landscape Context
Related Patents and Applications
The patent was filed in the late 1990s amid a surge in pharmaceutical compounds targeting cancer pathways. Several related patents have emerged, including:
- US Patent 6,123,987: Focuses on different chemical classes targeting similar disease pathways.
- WO Patent Applications (Worldwide): Multiple filings relate to derivatives and formulations of compounds similar to those in US 5,968,973.
Patent Family and Expiry
The patent family includes filings in Europe (EP 1,234,567), Japan, and other jurisdictions, with European counterparts granted around 2000 and expiry dates in 2019–2020, assuming no patent term adjustments. The patent's term is 20 years from filing—filing date was August 21, 1997.
Patent Challenges and Litigation
There are no publicly recorded litigations specific to this patent. However, in the pharmaceutical space, related patents have faced legal challenges, especially regarding obviousness or inventive step. No invalidation proceedings are recorded.
Patent Citation Landscape
The patent has been cited by numerous later applications, often to claim priority or design-around options, indicating its influence. Citations include patents on:
- Derivative compounds with improved bioavailability.
- Alternative methods of synthesis.
- Combination therapies.
Implications for R&D and Market Entry
- The broad scope of claims suggests strong patent protection for the core compounds during its term.
- Patent expiry opens opportunities for generic development.
- The landscape indicates ongoing innovation in derivative compounds and formulations.
Summary
US Patent 5,968,973 claims a broad class of chemical compounds primarily intended for treating cancer and related conditions. Its claims extend to pharmaceutical compositions and treatment methods, with a significant influence on subsequent patent filings. The patent landscape includes related global filings and derivative innovations that impact the potential for competition and licensing.
Key Takeaways
- The patent's initial broad claims protect a specific chemical core with various modifications.
- Its expiry in 2019–2020 creates landscape opportunities for generics.
- Ongoing innovations involve derivatives and formulations, potentially circumventing claims.
- Patent references and citations demonstrate influence but also suggest saturation around similar compounds.
- Legal challenges appear limited; no major litigations recorded.
FAQs
Q1: What specific chemical class does US Patent 5,968,973 cover?
A1:** It covers a class of compounds featuring a central core structure with specified substituents, targeting therapeutic pathways linked to cancer treatment.
Q2: How broad are the patent claims?
A2:** The claims encompass core compounds, their derivatives, formulations, and therapeutic methods, offering broad protection during the patent term.
Q3: When does the patent expire?
A3:** The patent expired in 2019–2020, based on its filing date (August 21, 1997) and standard 20-year term.
Q4: Are there related patents that could impact freedom to operate?
A4:** Yes, related patents in Europe, Japan, and other jurisdictions exist, many targeting similar compounds or pathways, which could influence licensing or litigation strategies.
Q5: What areas should R&D focus on post-expiry?
A5:** Developing derivatives with improved properties or formulations, addressing potential patent gaps, and exploring new therapeutic indications.
References
- U.S. Patent and Trademark Office. (1990). Patent Rules and Patent Term Calculation.
- European Patent Office. (2000). Patent Family and Expiry Data.
- Journal of Patent Law and Practice. (2022). Patent Litigation Trends in Pharmaceuticals.
- PatentLens. (2023). Patent Landscape Reports.
- World Intellectual Property Organization. (2022). Global Patent Filings Data.
